dbennett_recent

d a n i - b e n n e t t . c o m

[identity] DRC logo development. 2014.

DRC

DAVA RESEARCH CONSORTIUM

DAVA RESEARCHCONSORTIUM

DRCDAVA Research Consortium

...moving community cancer research forward

DAVA ResearchConsortium

DAVA ResearchConsortium

DRC


DAVA Research

Consortium

CONSORTIUMDAVA RESEARCH


CONSORTIUMDAVA RESEARCH...moving cancer research forward

[identity] ACT logo development. 2013.

ACTacceleratingclinical trials ACT

accelerating clinical trials

ACTaccelerating clinical trials

ACT accelerating clinical trials

accelerating clinical trials>>ACTaccelerating clinicaltrials

AcceleratingClinical TrialsCT


ACTaccelerating

clinical trials

ACTaccelerating clinical trials ACT












ACTaccelerating clinical trials

omom

mom OMI

OmI

omeONCOLOGY MEETING EXPERTS

omiONCOLOGY MEETING INNOVATION

oncologymeeting

INNOVATION


omiONCOLOGY MEETING I N N O V A T I O N S

mONCOLOGY MEETING INNOVATION



omeONCOLOGY MEETING

E X P E R T S




omeONCOLOGY MEETING

E X P E R T S




omeONCOLOGY MEETING

E X P E R T S


[identity] OMI logo development. 2013.

[identity] Bayou Gymnastics logo. 2013.

Bayou Preschoolbuilding the future

c: 432.664.6521o: 432.614.2291f: 432.614.2281

Greg Brady402 W.1st Street | Odessa, TX 79761

SSSSSSEEE

[identity] top: ESS logo. bottom: ESS business card. 2012.

[print] graduation surprise gift card. 2014.

P R O U D

CongratulationsW E A R E S O

O F Y O U

M A Y30thO

NL

Y Redeemable

[print] dual baby shower invite. 2014.

s h ow e rBaby

Join us for a

honoring

&JohnsonAlisa

ContrerasChristina

lunchj u ly 1 4 - 1 : 0 0

[print] Halloween party invite. 2014.

Halloween party

Lunch and beverages will be provided.

Costume coNtest - The best costumes will receive prizes!Employees can wear their costumes all day

(if it doesn’t interfere with visits, conferences, etc.)or prepare just before the party

dessert coNtest - Top desserts will receive prizes!

Friday, Octob er 3 11 : 00 - 3 :00

[print] Thanksgiving potluck invite. 2014.

Thanksgiving PoTluck!

Categories: dessert & non-dessert3 winners for each categoryPLUS a best overall winner!

Contest entries must be home-made. All other food brought does not have to be home made.

Sign up excel will be circulated to share what you’ll be bringing.

Wednesday, November 26

Traditional office bake-off !

12:00 pm - 2:00 pm

[print] fundraiser invitations, recurring project 2013 and 2014.

18th annual

CASINO

night

Viva Las VegasYou are cordially invited to attend the

benefi tting St. Peter the Apostle Catholic School1201 S. Cherry LaneFort Worth, TX 76108

11/9/13 6-11 pm

To purchase tickets, please call

817-246-2032Feeling luckyYou are cordially invited to attend the

benefitting St. Peter the Apostle Catholic School

1201 S. Cherry LaneFort Worth, TX 76108

To purchase tickets, please call

817-246-2032

19th annual Viva Las Vegas

Casino nightNOV. 8 6-11 pm

[print] top: outside banner. bottom: double-sided full-window decals. 2012.

& minds

rowing godly bodiesg

w e e k d a y e d u c a t i o nouths eminoles aptistb hurchc

Train children to live the right way, and when they are old, they will not stray from it.

Proverbs 22:6

& minds

rowing godly bodiesg

ouths eminolesw e e k d a y

aptistB hurchce d u c a t i o n

proverbs 22:6

Train children to live the right way, and when they are old,

they will not stray from it.

[advertising] AML summit brochure. 2014.

3Inaugural “ThInk Tank” on InTegraTIng new Molecular TargeTs In aMlnoveMber 8, 2014 | Dallas, TX

Inaugural “Think Tank” on

Integrating NewMolecular Targets AMLin

5 Welcome 7 AGeNDA UNDerstANDiNG A complex DiseAse GeNomic evAlUAtioN iN Aml 8 AGeNDA epiGeNetic ApproAches for Aml immUNe ApproAches to Aml 9 AGeNDA NeW tArGets strAteGies for the fUtUre 11 BioGrAphies 33 fAcUlty 40 UpcomiNG sUmmits

agendabiographies

faculty

33

Inaugural “ThInk Tank” on InTegraTIng new Molecular TargeTs In aMl

noveMber 8, 2014 | Dallas, TX

faculty

facultyInaugural “ThInk Tank” on InTegraTIng new Molecular TargeTs In aMl

biographiesInaugural “ThInk Tank” on InTegraTIng new Molecular TargeTs In aMl

SpeAkeRScamille Abboud, Md

Professor of Medicine

Washington University, St. Louis

Siteman Cancer Center

St. Louis, MO

omar Abdel-Wahab, Md

Assistant Member

Memorial Sloan-Kettering Cancer

CenterNew York, NY

Michael Andreeff, Md, Phd

Professor of Medicine and Paul

Mary Haas Chair in Genetics

Chief, Molecular Hematology &Therapy

University of Texas

MD Anderson Cancer Center

Houston, TX

daniel Arber, Md

Ronald F. Dorfman, MBBCH, FRCPATH

Professor in Hematopathology

Stanford University School of Medicine

Stanford, CA

david claxton, Md


Penn State Hershey Cancer Institute

Hershey, PA

Robert collins, Md

Sydney and J.L. Huffines Distinguished

Chair in Cancer Research

H. Lloyd and Willye V. Skaggs Professorship

in Medical Research

University of Texas Southwestern

Medical Center

Dallas, TX

stefan Faderl, Md

Chief, Leukemia

John Theurer Cancer Center

Hackensack, NJ

james Foran, Md

Associate Professor of Oncology

Mayo Clinic

Jacksonville, FL

stefan Fröhling, Md

ProfessorHead, Molecular & Cellular Oncology

SectionGerman Cancer Research Center

National Center for Tumor Diseases

Heidelberg, Germany

Leo Luznik, Md


Johns Hopkins University

Sidney Kimmel Comprehensive

Cancer Center

Baltimore, MD

Alexander Perl, Md

Assistant Professor of Medicine

University of Pennsylvania

Abramson Cancer Center

Philadelphia, PA

jeffrey Pu, Md, Phd

Assistant Professor of Medicine

Penn State Hershey Cancer Institute

Hershey, PA

jerald Radich, Md

Associate Professor of Medicine

Fred Hutchinson Cancer Research

CenterSeattle, WA

Farhad Ravandi-Kashani, Md


University of Texas


Houston, TX

jorge cortes, Md

Deputy Department Chair

Chair, AML Section

D. B. Lane Cancer Research Distinguished

Professor for Leukemia Research

University of Texas


Houston, TX

Mark Levis, Md, Phd

Director, Adult Leukemia Program


Johns Hopkins University

Sidney Kimmel Comprehensive

Cancer Center

Baltimore, MD

CHaIr

CHaIr

7

Inaugural “ThInk Tank” on InTegraTIng new Molecular TargeTs In aMl

noveMber 8, 2014 | Dallas, TX

agendaagendaInaugural “ThInk Tank” on InTegraTIng new Molecular TargeTs In aMl

SaTurDay | NoveMber 8, 2014

7:00 aM breakfast and registration

7:45 aM Welcome and introductions

John Eckardt

Understanding a Complex Disease Jorge Cortes

8:00 aM aML landscape 2015: How are patients treated?

Charles Schiffer

8:15 aM risk adapted approach to treatment of aML

Stefan Faderl

8:30 aM outpatient management of intensive aML therapy

David Claxton

8:45 aM Prognostic impact of FLT3 mutations and treatment decisions

Richard Schlenk

9:00 aM Changes in the classification of aML

Daniel Arber

9:15 aM DISCuSSIoN

Genomic Evaluation in AML Jerald Radich

9:30 aM genomic analysis of non-responders and single cell clonal evolution

Jerald Radich

9:45 aM relevance of gPI-anchor protein in genomic stability and leukemic

transformation

Jeffrey Pu

10:00 aM breaK

Inaugural “Think Tank” on

Four Seasons Resort & Club Dallas at Las Colinas

Dallas, TX

Integrating NewMolecular Targets AMLin

8:00 am - 5:30 pmNovember 8, 2014

Summit ChairsJorge Cortes, MD

University of Texas MD Anderson Cancer Center

Houston, TX

Mark Levis, MD, PhDJohns Hopkins University

Sidney Kimmel Comprehensive Cancer Center

Baltimore, MD

For More INForMaTIoN go To:

www.omionc.com

p r o s t a t eC A N C E R S U M M I T

Summit on Pract ica l and Emerging Trends in Prostate Cancer

1ST ANNUAL

REGISTRATION

w w w. o m i o n c . c o m

OLIVER SARTOR , MDProfessor

Tulane Univers ityNew Orleans , LA

N IC HOL AS VO G E L Z A NG , M DVice Chair SWO G GU Committee

C omprehensive Cancer C enters of NevadaL as Vegas , NV

S U M M I T C H A I R S

BALLROOMmeeting room

p r o s t a t eC A N C E R S U M M I T

Summit on Pract ica l and Emerging Trends in Prostate Cancer

1ST ANNUAL

Sunday, February 16, 2014

Genetic risk of prostate cancer: The story of common and rare variants Peter Nelson

Do chromosomal rearrangements determine poor clinical outcome in prostate cancer? (ETS, TMPRSS2-ERG) Scott Tomlins

Quantitative imaging methods for detecting metastasis and therapeutic response Glenn Liu

Predictive validity of PSA kinetics in initiation and response to chemotherapy Mitchell Gross

Prognostic biomarkers in prostate cancer Daniel Danila

Immune checkpoint blockade in prostate cancer: Clinical results and future challenges Charles Drake

Exploiting immunomodulatory antibodies in prostate cancer (new antibodies) Susan Slovin

Immunotherapy combination strategies Emmanuel Antonarakis

Cabozantinib: c-Met and VEGFR2 TKI in bone metastasis Daniel George

Sequencing and combination prospects of AR inhibitors William Figg

Therapeutic targeting of EGF family of ligands and receptors in prostate cancer William Gullick

Optimizing bone-seeking therapy in clinic Oliver Sartor

Microenvironment captives: Tasquinimod in mCRPC Walter Stadler

PARP1 inhibitors in targeted radiosensitization and resistance Karen Knudsen

Critical Determinants of Prostate CancerSusan Slovin & Walter Stadler

Immunotherapy: Implications and ChallengesPhilip Kantoff & Daniel Petrylak

New FrontiersRobert Dreicer & Daniel George

MyelomaMarch 27-28Whistler, BC Canada

MelanomaMay 3-4Dallas, TX

Pancreatic, Gastric, HCLTBD

LungDecember 13-14Dallas, TX

CLLMarch 29-30Whistler, BC Canada

Immune CheckpointsJuly 19-20Palm Beach, FL

Acute Lymphobastic LeukemiaAugust 23-24Dallas, TX

M A R M AY J U L S E P N O VA P R J U N A U G O C T D E C

Upcoming Cancer Summits for 2014

7:00 AM - 8:40 AM

9:00 AM - 10:20 AM

10:40 AM - 12:40 PM

[advertising] left: directional signage. right: large format agenda banner. 2014.

[advertising] OMI melanoma brochure. 2014.

Robert Andtbacka, MDAssistant ProfessorUniversity of Utah Huntsman Cancer InstituteSalt Lake City, UT

Nitin Chakravarti, PhDInstructorMD Anderson Cancer CenterHouston, TX

Adil Daud, MDClinical Professor Director, Melanoma Clinical ResearchUniversity of California, San Francisco Helen Diller Family Comprehensive Cancer CenterSan Francisco, CA

Michael Davies, MD, PhDAssociate ProfessorMD Anderson Cancer CenterHouston, TX

Madeleine Duvic, MDDeputy Department ChairMD Anderson Cancer CenterHouston, TX

Rene Gonzalez, MDProfessor of MedicineUniversity of Colorado Cancer CenterDenver, CO

Kenneth Grossmann, MD, PhDAssistant ProfessorUniversity of Utah Huntsman Cancer InstituteSalt Lake City, UT

Omid Hamid, MDChief, Translational Research and Immunotherapy Director, Melanoma TherapeuticsThe Angeles Clinic and Research InstituteLos Angeles, CA

Gerald Linette, MD, PhDAssociate Professor of MedicineWashington UniversitySt. Louis, MO

Doron Lipson, PhDDirector, Computational Biology MethodsFoundation MedicineCambridge, MA

Roger Lo, MD, PhDAssociate Professor of Medicine/ DermatologyUniversity of California, Los Angeles Jonsson Comprehensive Cancer CenterLos Angeles, CA

Patricia LoRusso, DOProfessor of Hematology and Oncology Director, Experimental TherapeuticsWayne State University Karmanos Cancer InstituteDetroit, MI

David McDermott, MDAssociate ProfessorDana-Farber Cancer InstituteBoston, MA

Martin McMahon, PhDDirector of Professional Education Co-Leader, Developmental Therapeutics ProgramUniversity of California, San Francisco Helen Diller Family Comprehensive Cancer CenterSan Francisco, CA

James Mier, MDAssociate ProfessorDana-Farber Cancer InstituteBoston, MA

Steven O’Day, MDDirector of Clinical Research Director of Los Angeles Skin Cancer InstituteBeverly Hills Cancer CenterBeverly Hills, CA

Elise Olsen, MDProfessor of Dermatology Professor of MedicineDuke UniversityDurham, NC

Sapna Patel, MDAssistant ProfessorMD Anderson Cancer CenterHouston, TX

Lauren Pinter-Brown, MDClinical Professor Director, UCLA Lymphoma ProgramUniversity of California, Los Angeles Jonsson Comprehensive Cancer CenterLos Angeles, CA

Douglas Reintgen, MDProfessor, College Of Medicine SurgeryUniversity of Southern Florida Lakeland Regional Cancer CenterTampa, FL

Alain Rook, MDDirector, Photopheresis Program Professor of DermatologyUniversity of Pennsylvania Abramson Cancer CenterPhiladelphia, PA

Merrick Ross, MDProfessor, Department of Surgical OncologyMD Anderson Cancer CenterHouston, TX

William Sharfman, MDAssociate Professor of Oncology and DermatologyJohns Hopkins University Sidney Kimmel Comprehensive Cancer CenterLutherville, MD

Jeffrey Sosman, MDProfessor of Medicine Director, Melanoma & Tumor Immunotherapy ProgramVanderbilt University Ingram Cancer CenterNashville, TN

Clifford Tepper, PhDAssociate Research BiochemistUniversity of California, DavisSacramento, CA

Jennifer Wargo, MDAssistant ProfessorMD Anderson Cancer CenterHouston, TX

Ian Watson, PhDPostdoctoral FellowMD Anderson Cancer CenterHouston, TX

Jeffrey Weber, MD, PhDSenior MemberMoffitt Cancer CenterTampa, FL

Martin Weinstock, MDProfessor of DermatologyBrown UniversityProvidence, RI

Michael Wong, MD, PhDProfessor of MedicineUniversity of Southern California Norris Comprehensive Cancer CenterLos Angeles, CA

FacULTY

Michael Atkins, MDGeorgetown University

Lombardi Comprehensive Cancer CenterWashington, DC

Patrick Hwu, MDMD Anderson Cancer Center

Houston, TX

CONfERENCE CHAIRMEN

T-cell MalignanciesMelanoma cutaneous&

accoMMoDaTIoNS

The Four Seasons Resort and Club Dallas

at Las Colinas is located in the hills of Irving,

Texas just minutes away from Downtown

Dallas and convenient to the Dallas/Fort

Worth International Airport (DFW) and Dallas

Love Field Airport (DAL). Exceptional service

in a retreat environment, an excellent location

for pleasure and business travel.

A small block of Superior rooms has been

set aside at a special rate of $185.00 plus

applicable taxes. In order to receive this

special rate, please call (972) 717-0700 and

identify yourself as part of the Summit on

Melanoma & Cutaneous T-cell Malignancies.

Room type and the special room rate is

subject to availability at the time of the

reservation. Note the room block will close on

April 11, 2014.

For questions, please email

Gregory Pynes at

[email protected].

TraVEL INForMaTIoN

The Four Seasons Resort and Club Dallas at

Las Colinas is conveniently located next to

Dallas/Fort Worth International Airport (DFW)

and Dallas Love Field Airport (DAL).

Registration fees include continental breakfast, working lunches, refreshment breaks and

syllabus materials.

First Name _____________________ Middle Initial ____ Last Name ___________________

Credentials: _______ c Physician c Fellow c PA-C c PhD c Pharmacist

Mailing Address _____________________________________________________________

Suite______ City __________________________ State _____ Postal/Zip Code __________

Phone Number_______________________________Fax ___________________________

E-mail ____________________________________________________________________

(your confirmation will be sent via e-mail.)

c Check here if you have any special dietary needs; please specify below:

___________________________________________________________________________

Please complete the registration form and mail it with your payment to the address below, or

visit www.regonline.com/heme to register online. Checks and credit cards are accepted. To

register by phone or fax, please call (214) 593-0504 or fax (214) 889-7070 (credit cards only).

Please make checks payable to Dava Oncology, LP.

Method of Payment

c Check c VISA c MasterCard c Discover c American Express

Name as it appears on credit card _______________________________________________

Signature __________________________________________________________________

Card Number _______________________________________________________________

Security Code ____________________________ Expiration Date _____________________

(On the back of most credit cards, front if American Express)

Billing Address (if different from above; zip code required):

Address ___________________________________________________________________

Suite______ City __________________________ State _____ Postal/Zip Code __________

Dava Oncology, LP fully complies with the legal requirements of the ADA and the rules and

regulations thereof. If any participant in this activity is in need of accommodations, please

notify us in order to receive service. Please call (214) 593-0504.

Please mail payments or inquires to:

Dava Oncology, LP

12400 Coit Road

Suite #980

Dallas, TX 75251

ThrEE WaYS To rEGISTEr

1.) Go to our web site:

www.regonline.com/heme

2.) Call or fax our office (credit card only)

p: (214) 593-0504

f: (214) 889-7070

3.) Complete the registration form and mail it

with your payment to the address below

(Checks and credit cards are accepted).

Dava Oncology, LP.

12400 Coit Road Suite #980

Dallas, TX 75251

Choose one of the following options:

Registration Option

c Live and On-Demand Access c Virtual Meeting and On-Demand Access

$325.00

$295.00


MK-3475 experience in melanoma

Omid Hamid

Inhibition of PD-L1 in melanoma

Patrick Hwu

Immunologic effects of BRAF inhibitor therapy

Jennifer Wargo

Sequence therapy with immune checkpoint and MAPK inhibitors

David McDermott

Novel combinations with immune checkpoint inhibitors

Jeffrey Weber

Role of HD IL-2 in the immune checkpoint era

Michael Wong

Debate: Should patients with BRAFmut metastatic melanoma

get a BRAF+/- MEK inhibitor first-line?

Breakout session

3:00 PM - 4:30 PM

Challenging cases for discussion

John Eckardt

Brain metastasis in melanoma therapy in the era of new immune

and targeted therapies

Clifford Tepper

Other skin Malignancies

7:00 AM - 8:45 AM

CTCL: Biology and current classification

Martin Weinstock

Treatment of early stage CTCL

Elise Olsen

Systemic therapy for CTCL

Alain Rook

Targeted therapy in clinical trials for CTCL

Madeleine Duvic

New therapies in development for CTCL at UCLA

Lauren Pinter-Brown

new targets in Melanoma

9:00 AM - 12:00 PM

Comprehensive genomic characterization of cutaneous

melanoma Ian Watson

Novel combination clinical trials for nivolumab in melanoma

TBD

NRAS and CDK targeted therapy in melanoma

Michael Davies

Current experience with c-KIT mutated melanoma

Adil Daud

Targeting ERK: PD-0325901

Patricia LoRusso

Biomarker analysis predicts antitumor activity of ipilimumab

Nitin Chakravarti

Immune related melanoma gene expression profile predicts for

neoadjuvant ipilimumab clinical benefit

Ahmad Tarhini

BISH RNAiSTMN1 nanoplex early assessment in melanoma

John Nemunaitis

Genomic and Prognostic evaluation of Melanoma

5:00 PM - 6:30 PM

The role of class 1 PI3’-kinases in the progression and

maintenance of BRAF mutated melanoma

Martin McMahon

Melanoma next generation sequencing: Biological and clinical

significance

Doron Lipson

Targeting p53 through HDM2 inhibition in melanoma

James Mier

Genetic and adaptive resistance to BRAF and MEK inhibitors

Roger Lo

Gene expression profiling as a predictor for early stage disease

Merrick Ross

advances in early stage Disease

6:45 PM - 8:00 PM

Melanoma nodal staging: The significance of non-sentinel lymph

node metastases

Douglas Reintgen

Surgical approach to locally advanced and advanced

melanoma Merrick Ross

advances in the standard of care for Melanoma

7:00 AM - 10:15 AM

Who can we cure with adjuvant therapy in melanoma?

Kenneth Grossmann

Where we were then and where we are now?

Michael Atkins

Immunotherapy: From IL-2 to TIL’s to CAR-T therapy

Patrick Hwu

Vemurafenib: promise and pitfalls

Steven O’Day

Best of both worlds: Increased activity & decreased toxicity of

BRAF/MEK combinations

Rene Gonzalez

Oncolytic immunotherapy: Unlocking its potential

TBD

Clinical activity of oncolytic immunotherapy in melanoma

Robert Andtbacka

Identifying the right patient for oncolytic immunotherapy

Howard Kaufman

targeting immune checkpoint inhibitors in Melanoma

10:30 AM- 3:00 PM

CTLA-4: A breakthrough in melanoma treatment

Gerald Linette

Getting the most out of ipilimumab combination

Sapna Patel

Toxicity management of immune checkpoint inhibitors

William Sharfman

Nivolumab single-agent and combination experience in

melanoma Jeffrey Sosman

FrIDaY | May 2

SaTUrDaY | May 3

SUNDaY | May 4

For more information or registrat ion, please v is itwww.regonl ine.com/heme

May 2nd-4th, 2014

F O U R SE AS ON S R E S ORT A N D C LU B

DA L L AS AT L AS C OL I NAS , T X

M ic ha e l at k i n s , M DDeputy Direc tor & Professor

Georgetown Univers ityLombardi C omprehensive Cancer C enter

Washington, D C

Pat r ic k h w u, M DDepar tment Chair

MD Anderson Cancer C enterHouston, T X

S U M M I T c h a I r S

1ST ANNUAL SUMMIT ON PRACTICAL AND EMERGING TRENDS IN


[advertising] large format retractable banner. 2014.

2014SUMMIT CALENDAR

MAR

FEB

MAY

JUL

AUG

SEP

DEC

ProstateFebruary 15-16 | Dallas, TX

Oliver Sartor, MDNicholas Vogelzang, MD

MyelomaMarch 27-28 | Whistler, BC Canada

Leif Bergsagel, MDSagar Lonial, MD

Sundar Jagannath, MD

MelanomaMay 3-4 | Dallas, TX

Michael Atkins, MDPatrick Hwu, MD

Harnessing the Immune SystemJuly 19-20 | Palm Beach, FL

Michael Atkins, MDDrew Pardoll, MD, PhD

Mario Sznol, MDSteve Rosenberg, MD, PhD

GI MalignanciesSeptember 27-28 | Dallas, TX

David Ilson, MD, PhDAlex Grothey, MD

LungDecember 13-14 | Dallas, TX

Paul Bunn, MDRoy Herbst, MD, PhDRavi Salgia, MD, PhD

Acute Lymphoblastic LeukemiaOctober 18-19 | Houston, TX

Jorge Cortes, MDCarl June, MD

Ching-Hon Pui, MD

Chronic LymphocyticLeukemiaMarch 29-30 | Whistler, BC Canada

John Byrd, MDRichard Furman, MD

Wyndham Wilson, MD, PhD

o m i o n c . c o m

[advertising] oncology meeting poster designs and syllabus layout. bottom: table tents. 2013.

MAPPLE EMERALD HOTELNEW DELHI

SEPTEMBER 16, 2013

KALA AZARALLEVIATION INITIATIVE

2ND ANNUAL

SEPTEMBER 20, 2013

INDIA MATERNAL HEALTH INIT IAT IVE MEET ING

MAPPLE EMERALD HOTELNEW DELHI

SEPTEMBER 20, 2013

2ND ANNUAL

Jawaharlal Nehru Medical College, Aligarh Muslim University

Imam BanoAligarh

India Maternal Health Initiative

Jawaharlal Nehru Medical College, Aligarh Muslim University

Imam Bano Aligarh

India Maternal Health Initiative

AGENDA

5:00 PM Discussion and Q&A5:30 PM ADJOURN7:00 PM Dinner and Social Event

SUNDAY, SEPTEMBER 15, 2013INDIAPOD AND DATA ANALYSIS8:30 AM Capabilities of the IndiaPOD and its use in Prospective Data Management and Analysis

Taizoon Khokhar and Dr. Vinay Jain8:45 PM Discussion and Q&A

RECENTLY ACTIVATED IPOI GRANT SITES Meeting Moderators: Dr. Vinay Jain9:00 AM Kamla Nehru Medical College, Allahabad

Dr. Sonia Tiwari 9:12 AM Nizam’s Institute of Medical Sciences

Dr. Vijay Gandhi Linga 9:24 AM Institute of Hematology, Medical College Kolkata

Dr. Kishore Kumar 9:36 AM Indira Gandhi Institute of Medical Sciences, Shimla

Dr. Ashwini Sood9:48 AM Nil Ratan Sarkar Medical College Hospital, Kolkata

Dr. Manik Mondal10:00 AM Indira Gandhi Institute of Medical Sciences, Patna

Dr. Rajesh Singh10:12 AM Thanjavur Cancer Hospital

Dr. Arun Seshachalam10:24 AM SSKM Institute of Post Graduate Medical Education & Research, Kolkata

Dr. Prafulla K. Mishra10:36 AM Government Medical College, Nagpur

Dr. Krishna Kamble10:48 AM Government Medical College, Jammu

Dr. Sanjeev Digra11:00 AM Tea Break11:30 AM The Role of the Private Practitioner in Improving Pediatric Oncology Outcomes

Dr. Ramandeep Arora, Max Superspecialty Hospital

INDIA PEDIATRIC ONCOLOGY MEETING

INDIA PEDIATRIC ONCOLOGY INITIATIVE MEETING

5TH ANNUAL

The purpose of the 2013 INDIA PEDIATRIC ONCOLOGY INITIATIVE (IPOI) Meet ing, in keeping with the mission of J iv Daya Foundat ion, is to enhance the infrastructure and del ivery of pediatr ic oncology care in India. The meet ing is designed as a forum where current strategies wi l l be reviewed and new ideas for J iv Daya Foundat ion to become involved in pediatr ic oncology efforts wi l l be discussed. Current grant recipients wi l l a lso report on the measurable impact that has been made through the IPOI partnership.

Outcomes of this meet ing should include the fol lowing:

• Tost imulatediscussionamongstcol leaguesto learnfromoneanotherandaddresscommonissues which are prevalent in pediatr ic oncology

• Toreviewtheut i l izat ionofgrantdol larsandassessthe impactmade,andtodiscusshowimpactwi l l be made in the future

• Todiscussopportuni t ies for increasingaccessibi l i ty topathological test ing

• To learnabout theavai labi l i tyof f inancial resourcesforpediatr iccancerpat ientsandconnect local donor agencies with inst i tut ions and pat ients in need

• To ident i fywaysofharnessingtechnologyto improveoutcomes

• Tounderstandthenextstepsforanalysisof dataanddiscussthepotent ial ut i l izat ionofprospect ive data in securing future grants or publ icat ion of research

• To ident i fyareasofneedandnewprojects for IPOIsupport

Mapple Emerald HotelNew Delhi, India

SEPTEMBER 14-15, 2013

[advertising] oncology clinic adboard materials. 2013.

Terrace RoomLobby Level

PI3K INHIBITORS IN NHL ADVISORY

BOARD

FRIDAY, NOVEMBER 1, 2013The Roosevelt Hotel

New York

meeting room:

Mark LevonyakPresident

PI3K INHIBITORS IN NHL ADVISORY

BOARD

[advertising] OMI multiple myeloma brochure. 2013.

U P C O M I N G C O N F E R E N C E S :

O N C O L O G Y M E E T I N G I N N O VAT I O N SA D I V I S I O N O F D AVA O N C O L O G Y

1 2 2 2 M E R I T D R . | D A L L A S , T X( 2 1 4 ) 3 6 0 - 7 4 7 3

CONFERENCE CONFERENCE

Immune CheckpointsSymposium on Immune Checkpoints

AUG 2-4 | DALLAS, TXConference Chairman: Sanjiv S. Agarwala, MD

Multiple MyelomaSymposium of Multiple Myeloma

SEP 6-8 | DALLAS, TXConference Chairman: J. Tate Thigpen, MD

Lung CancerLung Cancer Congress

NOV 1-3 | DALLAS, TXConference Chairman: ROY HERBST, MD, PHD

MelanomaSymposium on Melanoma and Other Cutaneous Malignancies

OCT 4-6 | DALLAS, TXConference Chairman: Oliver Sartor, MDDavid McLeod, MD

Prostate CancerProstate Cancer Congress

TBD | DALLAS, TXConference Chairman: Joyce O’Shaughnessy, MD

• Molecularlungcancerla

ndscapefor2013

• Newandemergingmolecu

lartargets

• Challengesinpersonaliz

inglungcancertherapy:tis

sueacquisition

• ManagingresistancetoE

GFRandALKTKIs

• Emergingtargetedagents

forNSCLCandSCLC

• Clinicaltrialdesignsfort

hemolecularera

• Newdiagnosticplatforms

forpersonalizedmedicine

• Newclinicaltrials

I N S I G H T S A N D O B J E C T I V E S :

technologyI N T E G R A T I O N

LIVE streamingandVIRTUAL meetingwithondemand

convenienceviewing

Keyword search optimization

l inkingtextandcommentsearchr

esultstothecorrespondi

ngvideo

andtranscripttext,toexp

editeindependentresear

chandmanagement

reporting

E-syllabus and web slide sharing

withoptimale-notessynchronizedt

othevirtualmeeting

Audience polling and surveys

providinginsightstoassi

stwithclinicalandcommercialdecisi

ons

multiple myeloma

G L O B A L T U M O R S U M M I T

C O N F E R E N C E C H A I R M A N

I N V I T E D F A C U L T Y

Bart Barlogie, MD, PhDposition

Brian Durie, MDposition

Rafael Fonseca, MDposition

Joseph Mikhael, MDposition

Nikhil Munshi, MDposition

Ruben Niesvizky, MDposition

Noopur Raje, MDposition

S. Vincent Rajkumar, MDposition

Paul Richardson, MDposition

David Vesole, MD, PhDposition

Ravi Vij, MDposition

Michael Wang, MDposition

Jeffrey Zonder, MDposition

Jesus San Miguel-Ayanz, EUposition

Michael Attal, EUposition

Antonio Palumbo, EUposition

Maria Mateos, EUposition

Pleter Sonneveld, EUposition

xxposition

1

2

3

4

A

B

C

ADCC Antibody Dependent Cell-mediated Cytotoxicity (ADCC): • Recognition of the Fc region of a

Mab by NK cells through the Fc-receptor (A) activates release of perforin and granzymes (B) that lyse the tumor cell (C)

CDC Complement Dependent Cytotoxicity (CDC): • Binding of the C1q complement

factor to the Fc region of a Mab (1), activates the proteolytic cascade of the complement classical pathway (2) to form a membrane-attackcomplex (3) resulting in lysis oftumor cells (4)

Direct Direct Cytotoxicity:• Recently described non-apoptotic

cell death activates a lysosomal-dependent pathway involving intracellular release of cathepsinproteases and subsequent membrane permeabilization (Alduaij et al., Blood. 2011; 117; p4529)

ADCC

CDC

Direct

multiple myelomaG L O B A L T U M O R S U M M I T

SEPTEMBER 6, 7, 8OMNI MANDALAY

DALLAS, TX

Oncology Meeting Innovations

technologyT H R O U G H

knowledgeA D V A N C I N G

[advertising] OMI lung cancer summit brochure. top, right: email campaign. 2013.

technologyI N T E G R A T I O N

INSIGHTS AND OBJECTIVES:- Molecular lung cancer landscape for 2013

- New and emerging molecular targets- Challenges in personalizing lung cancer therapy: tissue acquisition

- Managing resistance to EGFR and ALK TKIs- Emerging targeted agents for NSCLC and SCLC

- Clinical trial designs for the molecular era- New diagnostic platforms for personalized medicine

- New clinical trials

For Investigators and Research Staff December 14-15, 2013

Omni MandalayDallas, TX

Dear Investigator, You are cordially invited to attend the OMI Lung Cancer Global Tumor Summit . We encourage you to take advantage of this invitation by indicating your participation below, please note there are two options: _____ Yes, I am able to attend on this summit. _____ No, I am unable to attend. However, please extend the invitation to my colleague: (Name, email)_________________________________________________

You may reply by fax to 214-889-7070. For any questions, please call Gregory Pynes at 214-451-4519.

Sincerely,

OMI Staff division of DAVA Oncology

www.omi.com

INVITED FACULTYAlex Adjei, MD, PhD

Roswell Park Cancer Institute

Julie Brahmer, MD

Johns Hopkins

Ross Camidge, MD

University of Colorado Denver

David Gandara, MD

UC Davis Comprehensive Cancer Center

Barbara Gitlitz, MD

USC/Norris Comprehensive Cancer Center

Gavin Gordon, PhD

Brigham and Women’s Hospital

Ramaswamy Govindan, MD, PhD

Washington University School of Medicine

Raffit Hassan, MD

National Cancer Institute

John Heymach, MD, PhD


Anthony John Iafrate, MD, PhD

Massachusetts General Hospital

Edward Kim, MD

Carolinas HealthCare System

Kartik Konduri, MD

Texas Oncology

Corey Langer, MD

University of Pennsylvania School of Medicine

Patrick Ma, MD, MSc

Case Comprehensive Cancer Center

Tony Mok, MD

Prince of Wales Hospital, Shatin, HKSAR, China

Sai-Hong Ignatius Ou, MD, PhD

UC Irvine

William Pao, MD, PhD

Vanderbilt-Ingram Cancer Center

Suresh Ramalingam, MD

Emory School of Medicine

Rafael Rosell, MD, PhD

Germans Trias & Pujol Hospital, Barcelona, Spain

Charles Rudin, MD, PhD

Johns Hopkins

Alan Sandler, MD

OHSU

Joan Schiller, MD

UT Southwestern Medical Center

Lecia Sequist, MD, MPH


Geoffrey Shapiro, MD, PhD

Dana Farber Cancer Institute

Alice Shaw, MD


George Simon, MD


Mark Socinski, MD

University of Pittsburgh

Jean-Charles Soria, MD, PhD

Institut Gustave Roussy, Villejuif, France

David Spigel, MD

Tennessee Oncology/SCRI

Masahiro Tsuboi, MD, PhD

Yokohama City University Medical Center, Yokohama, Japan

Everett Vokes, MD

University of Chicago

Heather Wakelee, MD

Stanford University

Howard (Jack) West, MD

Swedish Cancer Institute

INVITED FACULTY

SESSION 1

BIOLOGY OF LUNG CANCER

TIME Sorting through Tumor Heterogeneity in

Lung Cancer

TIME Mutations and Translocations in Lung

Cancer: What do the Details Teach Us?

TIME TheInflamedTumorPhenotypeasa

PredictorofResponse

SESSION 2

TARGET-SPECIFICTREATME

NTOFLUNGCANCER

EGFR: Continuing Lessons

TIME Erlotinib – What Have We Learned

Since 2004?

TIME MechanismsofResistancetoEGFR

TKIs

TIME ApproachestoOvercomingtheT790M

Resistance Mutation

TIME TheNextGenerationsofEG

FR-

Targeted Agents

TIME Fully Human EGFR Antibodies in

Squamous NSCLC

TIME IsthereaRoleforEGFRInh

ibitionin

the Adjuvant Setting?

EML4-ALK: Discovering the Optimal Therapeutic

ApproachTIME ALKinPerspe

ctive:Identification

and Biology

TIME Crizotinib: Lessons Learned Since

Approval

TIME Next-Generation ALK Inhibitors

New Frontiers in Angiogenesis

TIME Bevacizumab–HowdoWeOptimize

theRoleofVEGFInhibition?

TIME TargetingtheVEGFR-2Extr

acellular

Domain

TIME TargetingtheDLL4/Notchp

athway

TIME InhibitorsoftheAng/Tieax

is

Integrating Immune Checkpoint Inhibitors in Lung

Cancer Therapy

TIME OverviewofImmuneCheckpoi

nts

TIME ImmuneCheckpointInhibitorsin

Development

TIME PracticalIssuesfortheApp

lication

AGENDA ofImmuneCheckpoi

ntInhibitorsin

LungCancer:OpenDiscus

sion

Combinations with MET Inhibitors

TIME BiologyofMET:WhatHaveWe

FoundinthePast12Months

?

TIME ThePathologist’sPerspecti

ve:What

ShouldWeBeMeasuringforMET

Inhibitors?

TIME METInhibitorsinDevelopm

ent:

Antibodies

Targeting the KRAS Pathway

TIME BiologyofKRASandBRAF

Mutations

TIME InhibitorsoftheKRASPath

wayand

AgentsforKRAS-mutantNSCLC

SESSION 3

CONTINUINGTHEOPTIMIZA

TIONOF

CHEMOTHERAPY

TIME WhatistheOptimalCytotoxicA

pproach

forSquamousNSCLC?

TIME CustomizedChemotherapy:Findingthe

Holy Grail

TIME Combinations with Cytotoxic Agents in

theAgeofTargetedTherapy

BREAKOUT SESSION 1

CASE-BASEDPATHWAYDEVELOPM

ENT

TIME GuidelinesforValue-based

CancerCare

TIME What Molecular Tests Should I Be

Ordering?

TIME WhatistheRoleofHistologyi

ntheAge

ofMolecularMarkers?

TIME Case-basedPanelDiscussi

on

BREAKOUT SESSION 2

EMERGINGAGENTS&PAT

HWAYS

TIME Chromosomal Translocations

TIME Beyond EGFR: New Growth Factor

ReceptorTargets

TIME HSP90Inhibitors

TIME CurrentStateofPI3KPathw

ay-

targeted Agents

TIME Antibody-drug Conjugates

SUMMIT IN

DECEMBER 14-15, 2013OMNI MANDAL AY

DALL AS, TX

CONFERENCE CHAIRMEN: ROY HERBST, MD, PHDYale UniversityPASI JANE, MD, PHDDana Farber Cancer Institute

PRACTICAL AND EMERGING AGENTS ININ LUNG CANCER

2013 SUMMIT ONPRACTICAL AND EMERGING AGENTS

IN LUNG CANCER

DECEMBER 14-15, 2013RITZ-C ARLTON | DALL AS, TX

ROY HERBST, MD, PHDYale UniversityNew Haven, CT

PASI JANNE, MD, PHDDana Farber Cancer Institute

Boston, MA

• Biology of Lung Cancer• Target-specific Treatment of Lung Cancer - EGFR: Continuing Lessons - EML4-ALK: Discovering Optimal Therapeutic Approach - New Frontiers in Angiogenesis - Integrating Immune Checkpoint Inhibitors in Lung Cancer Therapy - Combinations with MET Inhibitors - Targeting the KRAS Pathway• Continuing the Optimization of Chemotherapy• Case-based Pathway Development• Emerging Agents and Pathways

OMI’s Oncology Translational and Global Tumor Summits are designed to convene 80+ faculty and research consortia members, from some of the top academic and community centers across the nation, and our industry partners. These robust, 3-day summit programs are developed in collaboration with our medical staff and our world-renowned expert chairs. The faculty and scientific presenters are selected based on their ongoing research and peer-reviewed publications. The overall goal being to better understand new treatment options available within each therapeutic area, facilitate dynamic discussion and foster professional relationships.

OVERVIEW

AGENDA

20

NEXTPREV►◄ONE

Oncology SM

Your ONE source for cancer knowledge

1ST ANNUAL EXPERT FORUM ON ANGIOGENESIS | APRIL 26-27, 2013 • SCOTTSDALE, AZ

| DONALD MCDONALD, MD, PhDTargeting Resistance to Antiangiogenic Therapy

Dr. McDonald presented the first lecture on overcoming resistance to antiangiogenic agents.

The first part of his presentation addressed the question of what limits the activity of VEGF inhibitors in cancer therapy. VEGF inhibitors prune tumor blood vessels and slow tumor growth, which results in tissue hypoxia and changes in gene expression. One of the genes that may be upregulated is MET, which induces invasion and metastasis. Therefore, instead of turning a large tumor into a smaller, less malignant tumor, the result of VEGF pathway inhibition may be a smaller but more invasive tumor. Other mechanisms of resistance include revascularization and enhanced metastasis (Figure 1).1

To address this challenge, Dr. McDonald introduced two ways of simultaneously targeting the vasculature and the tumor (Table 1). The first approach is to block both VEGF and MET signaling. An example of this approach is cabozantinib, a TKI with activity against VEGFR-2 and MET, which was investigated in patients with castrate-resistant prostate cancer (CRPC). In a randomized phase II trial, bone scan improvement occurred in 68% of patients, 67% of patients experienced a corresponding reduction in pain, and 56% of patients experienced a decrease or discontinuation of pain medication.2 Two phase III trials are further investigating cabozantinib in CRPC. Although these results are encouraging, it is important to point out that the exact molecular targets in this setting have not yet been determined. The second approach is the addition of an oncolytic virus, such as JX-594, which in HCC has been shown to infect both tumor cells and tumor endothelial cells and therefore act in a complementary fashion to VEGF inhibitors.3

Dr. Bertolini asked if targeting pericytes might also be explored. Dr. McDonald said that question is being explored, but he believes resistance will eventually develop. Dr. Kerbel said that data from Dr. Napoleone Ferrara suggested that targeting pericytes disrupts the lung vasculature, which leads to increasing susceptibility to tumor cell infiltration.

• Blocking VEGF signaling initially inhibits tumors, but the resulting hypoxia changes tumor biology to a more invasive phenotype, which leads to resistance to therapy• Simultaneous targeting of VEGF and MET signaling might prevent tumor invasiveness• Targeting both tumor cells and tumor endothelial cells with an oncolytic virus might complement VEGF pathway inhibition

Q/A

Table 1. Potential Approaches to Evade Resistance to Antiangiogenic AgentsApproach ExampleCombined blockade of VEGF and MET signaling Cabozantinib

Infection of vascular and tumor cells by oncolytic virus JX-594

References:1. Pàez-Ribes et al., Cancer Cell. 2009; 15: p2202. Smith et al., J Clin Oncol. 2013; 31: p4123. Kirn and Thorne, Nat Rev Cancer. 2009; 9: p64

Figure 1. Overview of Mechanisms to Escape Antiangiogenic Therapy

42

NEXTPREV►◄

ONEOncologySM



Preclinical and Biology

Figure 1. Tumor Blood Vessel Heterogeneity and Differential Sensitivity to VEGF Inhibition

What is the True Importance of Angiogenesis in Cancer?

Harold Dvorak, MD>>• Humantumor

bloodvesselsareheterogen

eous(Figure1)

• Sometumorscanco-optexi

stingbloodvesselsanddono

trelyonangiogenesis

• Latevesselsinadvancedtum

orsmayloseVEGFdepende

ncy,sotargetingVEGFmayb

emoreeffectiveinearlier

tumors

• Otherangiogenicfactorssho

uldbetargeted,aswell

Q/A Dr. Hecht mentioned that the TML/VELOUR trials in CRC have

patients who have received antiangiogenic agents for a prolonged period of

time. The scans from these patients might be examined to investigate the

differences in progression patterns in the primary tumor versus metastases.

ONEOncologySM


2


NEXTPREV►◄

TABLE OF CONTENTS

Clicking on the ONE logo throughout the document

will bring you back to the Table of Contents.

3 INTRODUCTIONS

4 ABOUT DAVA

5 HIGHLIGHTS

6 VEGF SIGNALING

HOW DO WE OPTIMIZE THE USE OF ANTIANGIOGENIC TKIs?

12 Are Antiangiogenic TKIs Being Dosed Correctly? Eric Jonasch, MD

13 WhyDon’tAntiangiogenicT

KIsEnhancetheEfficacyo

fChemotherapy?Robert Kerbel, MD

14 ChemotherapyInducesMobilizat

ionofEndothelialProgenit

orCells(EPCs)

19 ShouldMetronomicChemotherapyBeU

sedWhenCombiningwith

Antiangiogenic TKIs? Francesco Bertolini, MD, PhD

OVERCOMING RESISTANCE TO ANGIOGENIC THERAPY

20 TargetingResistancetoAn

tiangiogenicTherapy

Donald McDonald, MD, PhD

21 ClinicalExperiencewithA

cquiredResistancetoAntia

ngiogenicAgents Roberto Pili, MD

22 ALK-1/Endoglin Signaling

NEXT-GENERATION TARGETS AND AGENTS

25 TargetingCD105(Endoglin

) Michael Gordon, MD

26 InhibitingActivinReceptor

-LikeKinase1(ALK-1)

Rupal Bhatt, MD, PhD, MMS

27 IntegrinInhibitors Andrew Mazar, PhD

DLL4/NOTCH SIGNALING

31 InhibitorsofDLL4/Notch

Adrian Harris, MD, DPHIL

32 Angiopoietin/TieSignaling

36 TargetingtheAngiopoietin

Pathway Hellmut Augustin, DVM, PhD

PREDICTING RESPONSE TO ANTIANGIOGENIC THERAPY

37 CandidatePredictiveBiom

arkers Murray Robinson, PhD

38 UsingImagingasaPredictiveMark

er Ronald Kord, MD, PhD

39 ImpactofOff-TargetEffectso

nAntiangiogenicAgents:T

oxicity

andEfficacy Howard West, MD

PREDICTING RESPONSE TO ANTIANGIOGENIC THERAPY

40 IsThereaRoleforAngioge

nesisInhibitionintheAdjuv

antSetting? Lee Ellis, MD, Randolph Hecht, MD

41 ChoosingtheOptimalAntiangiog

enicStrategyafterProgres

sion Randolph Hecht, MD

BIOLOGY AND PRECLINICAL DATA

42 WhatistheTrueImportanceofA

ngiogenesisinCancer?

Harold Dvorak, MD

43 ImpactofAntiangiogenicAge

ntsonHIFandCancerStem

Cells Giovanni Melillo, MD

43 ImprovingPreclinicalModels

forAntiangiogenicAgents

Robert Kerbel, PhD

44 MolecularMarkersofTumorEndotheliu

m Brad St. Croix, PhD

45 Angiocrine Signaling Lee Ellis, MD

46 BIOGRAPHIES

[advertising] executive summary booklet. 2013.

[advertising] new gym advertising. 2013.

PRODUCING TOP ELITE LIFTERSTrain with us:

Monday, Wednesday, FridaySunday

6:00 pm10:00 am

We support all federations.

[email protected]

Raw, single-ply, multi-ply...

All are welcome!

[advertising] rotating web banner campaign samples. 2012.

[advertising] Louisiana Tech powerlifting flyer. 2012.

[advertising] online course postcard. 2014

Secure registration-based access to summit curriculumQuiz-based curriculum designed to support the comprehension and

reinforcement of Summit highlights

15-20 hrsRecorded and Transcribed Summit content

6 MODULEswith Q&A

www.omiu.udemy.com

Incorporation of presentation slides, images, and videos

ONLINE OPENcurriculum

F R E E

Online course development through integration with an industry-leading massive open online course platform

[advertising] Unicef call-to-action poster. 2013.

It’s not his job...

It’s YOURS

against child laborSPEAK UP

www.unicef.org

[advertising] Unicef call-to-action poster. 2012.

LIGHTEN his load.SPEAK UP.

This is the weight of

SILENCE

www.unicef.org

[advertising] case study: magazine ad. 2012. Magazine Ad

[advertising] medical illustration examples.

Neck (cervical)lymph nodes

Node

Liver

Spleen

Groin (inguinal)lymph nodes

Armpit (axillary)lymph nodes

Lymphatic vessels

Bone marrow

Diaphragm

Thymus

Extracellular matrixImmune cells

Pancreatic cancer cells

Desmoplasticstroma

Hedgehog signal

Cancer cell Cancer-associatedfibroblastsproliferate

Blood vessel formation is limited;poor drug delivery


Lipoic acid

PDH Complex

NADH

NADHElectrons carried by NADH

Stage 1: GlycolosysGlucose Pyruvic acid

ATP ATP

Stage 2: Krebs cycle Stage 3:

Electron transport/chain/ATP synthase

action

Cytoplasm

Mitochondrion

CO2

CO2

Survival Proliferation

ATPATP

Incoming lymph vessel

Germinal center

Follicle

Medulla

Vein

Artery

Paracortex

Cortex

Outgoing lymph vessel


KDM TET

Nucleus

Cytoplasm

Altered epigenetic regulation

Altered differentiation and tumorigenesis

CH3 CH3

K G CA T

2-HGα-KG

IDH1/2mutant

4

Apoptosis(cell death)

1ADC in plasma

3ADC receptor complex is internalized

2 ADC binds to tumor-associated antigen to receptor

Cytoxic agent

Cancer cell

Dead cancer cell

[digital] ONE video platform. 2013.

TUMOR COMPASS

Lung Cancer

xxx

DOWNLOAD VIDEO AUDIO

Ribus mos re voluptis porehentias doloremposam ut pa ped quatibusda verspidia qui ullabo. Tate nim nonsece atistium lab ipsamen ditate porem arum rem remperro volorectota verias ad ulluptatem simoluptum quae recaece pudam, sin rem nis quam voluptas simet ut quam,

TUMOR COMPASS

Lung Cancer

xxx



HOME ABOUT SERVICES CONTACT

LOG IN Username

Password

LOG IN

TUMOR COMPASS

Lung Cancer

xxx



TUMOR COMPASS

Lung Cancer

xxx



TUMOR COMPASS

Lung Cancer

Rum latiandest pratempos quia sinullorum, qui arciatus sin nonsequodi as pro occuptae paruptate magnam vo-luptaqui debitas aliqui sequiscipici omnimodis si tet repere presequiamus sitam, cum andi ut magnis explite rerferu ptium, omnimus pore volorup taspero videbissint ut illandae seque duntinctiant porem ex ea aut qui dolupie ndisto que ipsaeped quam, sita con et denim que pro offictint.As aut ium nam ex essita doluptae nonsequos et pa sam eate consed unt quuntesed ma perum sed esciis re pere si id molumquis etus, sam quias cus essimpe ruptaeri dolupid quiatquibus, aut ut aut pla corepudanis ratur magnament utem enimolorundi accusciatius por sum quos dolor sequi solore vitem accus dolles accuptas moluptia cumquae omni rae ommolor aut venihitatem atur, odi dolliant aut que rectiunt este perions equiae. Pa poratus dandaes dolorib uscit, es dolor same niatur, soloreiumquo ipsus cusantium dolorum nis impereptat restis consenimpor sumIqui ario consequid qui blaborporia doluptatum et quaepe provit, omnihiciur aut eumque sam que omnihit iosanditate nobit

TABLE OF CONTENTS

DOWNLOADS

Chapter 1

Chapter 2

Chapter 3

Chapter 4

Chapter 5

John Eckardt, MDEbis adit fuga. Utaspitat.Oditat. Repta dero moluptae. Nament pel invelique aut utentias doluptat qua-tatur re sime nihilla cessitat ut eniantio

BREAST COMPASS- John Eckardt, MD

LUNG COMPASS- John Eckardt, MD

CLL COMPASS- John Eckardt, MD

Audio

Video

Transcript

[advertising] educational tool. 2012.

“In multivariate analysis, luminal/HER2 and HER2-enriched tumors were associated with a significantly higher rate of brain, liver, and lung metastases.”

- Kennecke et al., J Clin Oncol. 2010

“HER2 overexpression was predictive of CNS involvement by multivariate analysis.”

- Miller et al., Ann Oncol. 2003

HER2 amplification correlates with

increased risk of metastasis 02

HER2+HER2 amplification correlates with increased risk of metastasisEvery HER2+ visceral patient is high-risk, regardless of HR status

Subthemes References

Supportive referenceHER2+ mBC patients develop CNS metastases more readily than HER2- patients

Miller et al., Ann Oncol. 2003Gabos et al., J Clin Oncol. 2006

Additional referencesPreclinical

HER2-overexpressing NCI-H460 cells exhibit increased metastatic potential in vivo and in vitro Yu et al., Cancer Res. 1994

MetastaticCorrelation between lymph node metastases and HER2 overexpression in node-positive breast cancer patients

Slamon et al., Science. 1987Slamon et al., Science. 1989

Greater risk of CNS metastasis associated with HER2+ status than with other prognostic factors Pestalozzi et al., Ann Oncol. 2006

Metastases at multiple sites are more common in HER2-enriched breast cancer patients

Kennecke et al., J Clin Oncol. 2010

ReviewPositive HER2 status is predictive of increased CNS metastasis risk Nguyen et al., Neurol Clin. 2007

Nahta et al., Cancer Res. 2004

HER2+To target HER2, trastuzumab alone is now suboptimal

Dual blockade more efficiently inhibits breast cancer growth in trastuzumab-resistant cells

> Back to reference page

Impact and Statements• The current preclinical study determined

the ability of combined anti-HER2 therapy to inhibit breast cancer cell proliferation and survival in HER2-overexpressing BT474 cells

• Dual blockade more efficiently inhibited breast cancer growth than either agent independently

Anti-HER2 Combination Inhibits Breast Cancer Growth• BT474 cells were treated with trastuzumab

and/or the HER2/HER3 dimer inhibitor at a fixed 1:1 ng/ml drug concentration ratio; dual blockade mediated a loss of up to 60% of cells at doses in which cells were resistant to trastuzumab or the HER2/HER3 dimer inhibitor alone

Anti-HER2 Combination Induces Apoptosis• Cell cycle analysis was performed to

determine whether the results of the dose-response assays were due to cell cycle arrest or apoptosis

• Dual blockade increased the subdiploid fraction; in addition, the anti-HER2 combination reduced the percentage of proliferating (S-phase) cells

RN=469

Chemotherapy- HER2+ metastatic breast cancer- No prior chemotherapy for metastatic disease

Chemotherapy +trastuzumab

12 wks

24 wks

36 wks

48 wks

-5

5

15

Mea

n C

hang

e in

Sco

re

-15

0

NR R

Global QOL

NR R

Physical

NR R

Social

NR R

Role

NR R

Fatigue

10

-10

HER2+metastatic breast cancercreated by ONE Oncology

[advertising] rotating web banner. 2013.

[advertising] web banner samples. 2013.

PREVENTION & DIAGNOSTIC E V A L U A T I O N

O F N S C LC

A DVA N C E DM E T A S T A T I C

EVOLUTION OF CARE-LOCALLY

L U N G C A N C E R

&

A D V A N C E S I N T H E R A P Y F O R

E G F R mut & A L K R E A R R A N G E D

L U N GC A N C E R

I N N S C L C

E V O L V I N G R O L E O F

VEGF & MET

dbennett_recent

Documents

Transcript of dbennett_recent